40230-24-8|4,6-Diphenylpyrimidin-2-amine| Ambeed

CAS No. :	40230-24-8
Formula :	C₁₆H₁₃N₃
M.W :	247.30
SMILES Code :	NC1=NC(C2=CC=CC=C2)=CC(C3=CC=CC=C3)=N1
MDL No. :	MFCD00234910
InChI Key :	KZUCBEYDRUCBCS-UHFFFAOYSA-N
Pubchem ID :	619024

Safety of [ 40230-24-8 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

Computational Chemistry of [ 40230-24-8 ] Show Less

Physicochemical Properties

Num. heavy atoms	19
Num. arom. heavy atoms	18
Fraction Csp3	0.0
Num. rotatable bonds	2
Num. H-bond acceptors	2.0
Num. H-bond donors	1.0
Molar Refractivity	77.31
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	51.8 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.53
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	3.18
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	3.4
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.49
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.28
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.98

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.95
Solubility	0.028 mg/ml ; 0.000113 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-3.94
Solubility	0.0285 mg/ml ; 0.000115 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-6.33
Solubility	0.000115 mg/ml ; 0.000000465 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Poorly soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	Yes
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	Yes
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	Yes
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	Yes
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.55 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.04

Application In Synthesis of [ 40230-24-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 40230-24-8 ]

[ 40230-24-8 ] Synthesis Path-Downstream 1~54

1
[ 62961-62-0 ]
[ 593-85-1 ]
[ 40230-24-8 ]

References: [1]Journal of the American Chemical Society,1946,vol. 68,p. 99.

2
[ 593-85-1 ]
[ 120-46-7 ]
[ 40230-24-8 ]

References: [1]Journal of the American Chemical Society,1946,vol. 68,p. 99.

3
[ 40230-24-8 ]
[ 1484-88-4 ]
1-(4,6-diphenyl-2-pyrimidinyl)-2,4,6-triphenylpyridinium perchlorate [ No CAS ]

References: [1]Chemistry of Heterocyclic Compounds,1980,vol. 16,p. 574 - 578.
Khimiya Geterotsiklicheskikh Soedinenii,1980,p. 748 - 752.

4
[ 40230-24-8 ]
[ 108-24-7 ]
[ 58413-41-5 ]

References: [1]Journal of Heterocyclic Chemistry,1982,vol. 19,p. 1087 - 1092.

5
[ 40230-24-8 ]
[ 103-72-0 ]
[ 102936-62-9 ]

References: [1]Journal of the Indian Chemical Society,1985,vol. 62,p. 71 - 73.

6
[ 87286-05-3 ]
[ 40230-24-8 ]

References: [1]Journal of Heterocyclic Chemistry,1983,vol. 20,p. 691 - 696.

7
[ 70769-74-3 ]
[ 113-00-8 ]
[ 40230-24-8 ]

References: [1]Journal of Heterocyclic Chemistry,1985,vol. 22,p. 405 - 407.

8
[ 113-00-8 ]
[ 52762-77-3 ]
[ 40230-24-8 ]

References: [1]Monatshefte fur Chemie,1985,vol. 116,p. 385 - 400.

9
[ 50-01-1 ]
[ 94-41-7 ]
[ 40230-24-8 ]

Yield	Reaction Conditions	Operation in experiment
	With potassium hydroxide; In ethanol; for 10h;Reflux;	1,3-Diphenyl propen-2-one (0.01mol) (1) were taken in a 250 mL round bottom flask and dissolved in ethanol (25 mL). To this guanidine chloride (0.01 mol) and ethanolic KOH (5 mL of 40 %) were added. The reaction mixture was refluxed for 10 h. The mixture was then poured into water (ice-cold) and neutralized with dil. HCl. After neutralization, the solid was filtered, washed with excess of water, dried and recrystallized from ethanol from ethanol to give pure product. Spectral data for compound 2: The IR of compound 2 exhibited nu (C=C) stretching = 1537-1494 cm-1, nu(N-H) (1 amine) stretching = 3302 cm-1 and 3475 cm-1, nu (C-N) stretching = 1220.98 cm-1, nu(C-H)(Sp2) stretching = 3180.72 cm-1. 1H NMR (400 MHz, DMSO-d6) delta ppm: 3.43 (s, 3H,-OCH3), 5.1 (s, 2H, -NH2), 7.0 to 8.0 (m, 20H, Ar-H and NH) [9].

References: [1]Chemistry and biodiversity,2013,vol. 10,p. 2267 - 2277.
[2]Medicinal Chemistry Research,2014,vol. 23,p. 2976 - 2984.
[3]Asian Journal of Chemistry,2010,vol. 22,p. 5581 - 5587.
[4]Chemical Biology and Drug Design,2017,vol. 89,p. 797 - 805.
[5]Journal of Heterocyclic Chemistry,1982,vol. 19,p. 1087 - 1092.
[6]New Journal of Chemistry,2016,vol. 40,p. 2541 - 2546.
[7]Journal of Heterocyclic Chemistry,2017,vol. 54,p. 524 - 530.
[8]Asian Journal of Chemistry,2017,vol. 29,p. 2084 - 2090.
[9]Journal of Heterocyclic Chemistry,2018,vol. 55,p. 1024 - 1032.

10
[ 50-01-1 ]
[ 7338-94-5 ]
[ 40230-24-8 ]

References: [1]Journal of Heterocyclic Chemistry,1983,vol. 20,p. 691 - 696.
[2]Chemistry - A European Journal,2010,vol. 16,p. 89 - 94.

11
[ 506-93-4 ]
[ 614-47-1 ]
[ 40230-24-8 ]

References: [1]European Journal of Medicinal Chemistry,2010,vol. 45,p. 1583 - 1589.
[2]Journal of Heterocyclic Chemistry,1985,vol. 22,p. 1551 - 1557.
[3]Journal of the Korean Chemical Society,2010,vol. 54,p. 49 - 54.
[4]Journal of Heterocyclic Chemistry,2013,vol. 50,p. 396 - 402.

13
[ 6935-75-7 ]
[ 50-01-1 ]
[ 40230-24-8 ]

References: [1]Journal of the Indian Chemical Society,2002,vol. 79,p. 190 - 190.

14
[ 58544-41-5 ]
[ 40230-24-8 ]

References: [1]Tetrahedron,2003,vol. 59,p. 655 - 662.

15
[ 4524-93-0 ]
[ 40230-24-8 ]
cyclopentanecarboxylic acid-(4,6-diphenyl-pyrimidin-2-yl)-amide [ No CAS ]